Jürgen Honegger1, Isabella Nasi-Kordhishti2, Nuran Aboutaha2, Sabrina Giese2. 1. Department of Neurosurgery, University of Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany. juergen.honegger@med.uni-tuebingen.de. 2. Department of Neurosurgery, University of Tübingen, Hoppe-Seyler-Straße 3, 72076, Tübingen, Germany.
Abstract
PURPOSE: Renewed interest in transsphenoidal surgery (TSS) as a therapeutic option for prolactinomas has emerged. METHODS: Based on contemporary literature and own experience, the changing role of surgery for treatment of prolactinomas is discussed. RESULTS: Today, TSS is performed by minimally invasive microscopic or endoscopic techniques. Normoprolactinemia is obtained in 71-100% of patients with microprolactinomas by TSS. Almost equal results are found in circumscribed intrasellar macroprolactinomas. In experienced hands, pituitary function is preserved in TSS. The risk of cardiac valve disease is still a concern with ergot-derived dopamine-agonists (DAs) in patients requiring long-term, high-dose dopamine-agonist (DA) treatment. Cost-utility analysis favors TSS over DA treatment. The possible negative impact of DA treatment on future surgical results is still a controversial and unsettled issue. In patients who wish to become pregnant, the advantages of microprolactinoma removal to avoid DAs and macroprolactinoma debulking to avoid symptomatic enlargement during pregnancy should be discussed with the patients. Young patients' age is an argument for surgery to circumvent the unpredictable sequelae of long-term DA treatment. Surgery should be discussed in male gender because of a higher likelihood of DA resistance and aggressive behavior of prolactinoma. CONCLUSION: Given excellent results of TSS and concerns about medical treatment, the scale of indications for TSS as an alternative to DAs has increased. The patient's wishes concerning a chance at a cure with TSS instead of a long-term treatment with DAs has become an important and accepted indication. With DA medication and TSS, two effective treatment modalities for prolactinomas are available that can be used in a complementary fashion.
PURPOSE: Renewed interest in transsphenoidal surgery (TSS) as a therapeutic option for prolactinomas has emerged. METHODS: Based on contemporary literature and own experience, the changing role of surgery for treatment of prolactinomas is discussed. RESULTS: Today, TSS is performed by minimally invasive microscopic or endoscopic techniques. Normoprolactinemia is obtained in 71-100% of patients with microprolactinomas by TSS. Almost equal results are found in circumscribed intrasellar macroprolactinomas. In experienced hands, pituitary function is preserved in TSS. The risk of cardiac valve disease is still a concern with ergot-derived dopamine-agonists (DAs) in patients requiring long-term, high-dose dopamine-agonist (DA) treatment. Cost-utility analysis favors TSS over DA treatment. The possible negative impact of DA treatment on future surgical results is still a controversial and unsettled issue. In patients who wish to become pregnant, the advantages of microprolactinoma removal to avoid DAs and macroprolactinoma debulking to avoid symptomatic enlargement during pregnancy should be discussed with the patients. Young patients' age is an argument for surgery to circumvent the unpredictable sequelae of long-term DA treatment. Surgery should be discussed in male gender because of a higher likelihood of DA resistance and aggressive behavior of prolactinoma. CONCLUSION: Given excellent results of TSS and concerns about medical treatment, the scale of indications for TSS as an alternative to DAs has increased. The patient's wishes concerning a chance at a cure with TSS instead of a long-term treatment with DAs has become an important and accepted indication. With DA medication and TSS, two effective treatment modalities for prolactinomas are available that can be used in a complementary fashion.
Entities:
Keywords:
Dopamine-agonists; Endocrinological outcome; Hyperprolactinemia; Hypopituitarism; Prolactinoma; Transsphenoidal surgery
Authors: Felipe F Casanueva; Mark E Molitch; Janet A Schlechte; Roger Abs; Vivien Bonert; Marcello D Bronstein; Thierry Brue; Paolo Cappabianca; Annamaria Colao; Rudolf Fahlbusch; Hugo Fideleff; Moshe Hadani; Paul Kelly; David Kleinberg; Edward Laws; Josef Marek; Maurice Scanlon; Luis G Sobrinho; John A H Wass; Andrea Giustina Journal: Clin Endocrinol (Oxf) Date: 2006-08 Impact factor: 3.478
Authors: Lukas Andereggen; Janine Frey; Robert H Andres; Markus M Luedi; Jan Gralla; Gerrit A Schubert; Jürgen Beck; Luigi Mariani; Emanuel Christ Journal: J Clin Transl Endocrinol Date: 2021-06-17
Authors: Renato Cozzi; Maria Rosaria Ambrosio; Roberto Attanasio; Claudia Battista; Alessandro Bozzao; Marco Caputo; Enrica Ciccarelli; Laura De Marinis; Ernesto De Menis; Marco Faustini Fustini; Franco Grimaldi; Andrea Lania; Giovanni Lasio; Francesco Logoluso; Marco Losa; Pietro Maffei; Davide Milani; Maurizio Poggi; Michele Zini; Laurence Katznelson; Anton Luger; Catalina Poiana Journal: Eur J Endocrinol Date: 2022-02-03 Impact factor: 6.664
Authors: Grzegorz Zielinski; Marcin Ozdarski; Maria Maksymowicz; Katarzyna Szamotulska; Przemysław Witek Journal: Front Endocrinol (Lausanne) Date: 2020-07-07 Impact factor: 5.555
Authors: Merel van der Meulen; Amir H Zamanipoor Najafabadi; Daniel J Lobatto; Wilbert B van den Hout; Cornelie D Andela; Ingrid M Zandbergen; Alberto M Pereira; Wouter R van Furth; Thea P M Vliet Vlieland; Nienke R Biermasz Journal: Pituitary Date: 2020-10-06 Impact factor: 4.107
Authors: L Andereggen; J Frey; R H Andres; M M Luedi; M El-Koussy; H R Widmer; J Beck; L Mariani; R W Seiler; E Christ Journal: J Endocrinol Invest Date: 2021-04-13 Impact factor: 4.256